Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels
Status:
Withdrawn
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The objective is to conduct an exploratory study on the effect of Omalizumab on COPD patients
with elevated IgE. Exploratory outcomes include to determine whether Omalizumab use: reduces
exacerbations in COPD patients; or improves rescue medication use, decreases ICS use,
modified Medical Research Council (MMRC) dyspnea score, St. George's Respiratory
Questionnaire (SGRQ), 6-minute walk distance (6MWD), forced expiratory volume at one second
(FEV1)(the latter 3 with BMI make up the BODE score), residual volume (RV), total lung
capacity (TLC), exhaled nitric oxide (ENO), and determination C-reactive protein (CRP).